Ensign Peak Advisors
INZY

Ensign Peak Advisors’s Inozyme Pharma INZY Stock Holding History

Ensign Peak Advisors’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-7,991
Closed -$93K – 2215
2021
Q3 		$93K Hold
7,991
– – ﹤0.01% 1802
2021
Q2 		$136K Hold
7,991
– – ﹤0.01% 1759
2021
Q1 		$158K Hold
7,991
– – ﹤0.01% 1750
2020
Q4 		$165K Hold
7,991
– – ﹤0.01% 1740
2020
Q3 		$210K Buy
+7,991
New +$198K ﹤0.01% 1662

Other funds holding INZY

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ensign Peak Advisors's INZY Position: Q4 2021 in Review

Ensign Peak Advisors sold out of Inozyme Pharma (INZY) in Q4 2021, closing a stake of 7,991 shares — an estimated $93K sold.

Ensign Peak Advisors first reported a position in INZY in Q3 2020 and held it in 5 quarters. The position peaked at $210K in Q3 2020. 51 funds tracked by Wall St. Rank hold INZY as of Q4 2021.

  • Ensign Peak Advisors reported no remaining Inozyme Pharma position as of Q4 2021 after selling out during the quarter.
  • Ensign Peak Advisors sold 7,991 Inozyme Pharma shares in Q4 2021, an estimated $93K.
  • Ensign Peak Advisors first reported a position in Inozyme Pharma in Q3 2020 and held it in 5 quarters.
  • Ensign Peak Advisors's Inozyme Pharma position peaked at $210K in Q3 2020.
  • 51 funds tracked by Wall St. Rank held Inozyme Pharma as of Q4 2021.

Based on Ensign Peak Advisors's 13F filing for Q4 2021, filed 11 Feb 2022.